| Not Yet Recruiting | Benmelstobart in Combination With Anlotinib and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent NCT07489300 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 2 |
| Not Yet Recruiting | Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous NCT07432594 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 |
| Recruiting | CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial NCT07322094 | TORL Biotherapeutics, LLC | Phase 1 / Phase 2 |
| Recruiting | Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resista NCT06856499 | University of Colorado, Denver | Phase 1 |
| Recruiting | A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine NCT06890338 | AbbVie | Phase 2 |
| Not Yet Recruiting | Phase II Clinical Study of Utidelone Capsule (UTD2) in Patients With Advanced Epithelial Ovarian, Fallopian Tu NCT07044349 | Beijing Biostar Pharmaceuticals Co., Ltd. | Phase 2 |
| Recruiting | A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant NCT06994195 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 3 |
| Recruiting | PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombinati NCT07472140 | N.N. Alexandrov National Cancer Centre | Phase 2 / Phase 3 |
| Recruiting | Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer NCT06787612 | Regeneron Pharmaceuticals | Phase 2 |
| Withdrawn | A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Vari NCT04889495 | Pfizer | — |
| Recruiting | A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus NCT06824467 | Merck Sharp & Dohme LLC | Phase 3 |
| Recruiting | REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors NCT06710548 | Dana-Farber Cancer Institute | N/A |
| Withdrawn | A Clinical Study to Observe How Well That BAT8006 Works on Patients With Platinum Resistance Ovarian Cancer NCT06545617 | Bio-Thera Solutions | Phase 1 / Phase 2 |
| Completed | RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal NCT06173037 | RemeGen Co., Ltd. | Phase 2 |
| Recruiting | HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer NCT06014190 | Hansoh BioMedical R&D Company | Phase 2 |
| Withdrawn | Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi NCT05126342 | AGO Research GmbH | Phase 2 |
| Not Yet Recruiting | First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer NCT06063070 | Sun Yat-sen University | Phase 2 |
| Recruiting | Study of AVZO-021 in Patients With Advanced Solid Tumors NCT05867251 | Avenzo Therapeutics, Inc. | Phase 1 / Phase 2 |
| Terminated | REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Cho NCT05870748 | Sutro Biopharma, Inc. | Phase 2 / Phase 3 |
| Unknown | Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PA NCT05065021 | University Health Network, Toronto | Phase 2 |
| Recruiting | Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian NCT05739981 | Imunon | Phase 1 / Phase 2 |
| Recruiting | Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype NCT05574673 | Nordic Society of Gynaecological Oncology - Clinical Trials Unit | — |
| Unknown | Bevacizumab Plus Modiifed FOLFIRINOX in Ovarian, Fallopian Tube, or Primary Peritoneal Mucinous Carcinoma NCT05665023 | Yonsei University | Phase 2 |
| Active Not Recruiting | Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expr NCT05456685 | AbbVie | Phase 2 |
| Completed | Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer NCT05494580 | Sun Yat-sen University | Phase 1 / Phase 2 |
| Recruiting | Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherap NCT05281471 | Genelux Corporation | Phase 3 |
| Terminated | Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT) NCT05329545 | Mersana Therapeutics | Phase 3 |
| Terminated | Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithe NCT05092360 | Mural Oncology, Inc | Phase 3 |
| Active Not Recruiting | TAME: A Pilot Study of Weekly Paclitaxel, Bevacizumab, and Tumor Associated Macrophage Targeted Therapy (Zoled NCT05053750 | M.D. Anderson Cancer Center | EARLY_Phase 1 |
| Recruiting | A Beta-only IL-2 ImmunoTherapY Study NCT05086692 | Medicenna Therapeutics, Inc. | Phase 1 / Phase 2 |
| Withdrawn | Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer NCT04510584 | University Health Network, Toronto | Phase 2 |
| Unknown | Trial of Surufatinib Combined With Toripalimab in the Treatment of Peritoneal Metastatic Carcinoma of Gastroin NCT05030246 | Peking University | Phase 2 |
| Recruiting | Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant C NCT04606914 | University of Alabama at Birmingham | Phase 2 |
| Recruiting | A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors NCT04657068 | Artios Pharma Ltd | Phase 1 / Phase 2 |
| Recruiting | A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplima NCT04590326 | Regeneron Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Niraparib as Maintenance Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer NCT04546373 | Grupo Español de Investigación en Cáncer de Ovario | — |
| Completed | Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO St NCT04539327 | Grupo Español de Investigación en Cáncer de Ovario | — |
| Completed | Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ova NCT04227522 | North Eastern German Society of Gynaecological Oncology | Phase 3 |
| Unknown | A Clinical Study of Gimatecan in Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer or Primary Peritone NCT04029909 | Lee's Pharmaceutical Limited | Phase 1 |
| Active Not Recruiting | A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors NCT03872947 | Toray Industries, Inc | Phase 1 |
| Completed | Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer NCT03759587 | Takeda | Phase 2 |
| Completed | Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer NCT03759600 | Takeda | Phase 2 |
| Active Not Recruiting | Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2) NCT03393884 | Imunon | Phase 1 / Phase 2 |
| Completed | A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated NCT03635489 | Hoffmann-La Roche | Phase 3 |
| Terminated | A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Ad NCT03311334 | Sumitomo Pharma America, Inc. | Phase 1 / Phase 2 |
| Completed | A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies NCT03329950 | Celldex Therapeutics | Phase 1 |
| Completed | Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int NCT03213964 | Masonic Cancer Center, University of Minnesota | Phase 1 |
| Completed | A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With NCT03245892 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Terminated | Collection of Malignant Ascites, Pleural Fluid, and Blood From People With Solid Tumors NCT03189108 | National Cancer Institute (NCI) | — |
| Completed | Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab NCT03093155 | Yale University | Phase 2 |
| Completed | Homologous Recombination Inquiry Through Ovarian Malignancy Investigations NCT03159572 | Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan | — |
| Terminated | Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interfer NCT02948426 | National Cancer Institute (NCI) | Phase 1 |
| Completed | The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors NCT03507543 | Impact Therapeutics, Inc. | Phase 1 |
| Active Not Recruiting | Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery NCT02884648 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Factors Associated With the Use of a High Volume Cancer Center by Black Women With Ovarian Cancer: A Qualitati NCT02928549 | Memorial Sloan Kettering Cancer Center | — |
| Completed | A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer NCT02737787 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Completed | Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubic NCT02606305 | ImmunoGen, Inc. | Phase 1 / Phase 2 |
| Completed | Intraoperative Intraperitoneal Chemoperfusion to Treat Peritoneal Minimal Residual Disease in Stage III Ovaria NCT02567253 | University Hospital, Ghent | Phase 2 |
| Completed | Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian C NCT02480374 | Imunon | Phase 1 |
| Unknown | p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Ca NCT02435186 | Shenzhen SiBiono GeneTech Co.,Ltd | Phase 2 |
| Terminated | Autologous OC-L Vaccine and Ovarian Cancer NCT02452775 | Abramson Cancer Center at Penn Medicine | Phase 1 |
| Completed | Flaxseed as Maintenance Therapy for Ovarian Cancer Patients in Remission NCT02324439 | Southern Illinois University | Phase 1 |
| Terminated | Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer NCT02278783 | University of Utah | Phase 2 |
| Active Not Recruiting | "Re-Stimulated" TILs and IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Ca NCT01883297 | University Health Network, Toronto | Phase 1 |
| Withdrawn | Tai-chi / Qi-gong in Patients With Patients With Gynecological Malignancies NCT01880996 | Sheba Medical Center | Phase 1 / Phase 2 |
| Terminated | GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer NCT02012192 | Medical University Innsbruck | Phase 1 / Phase 2 |
| Completed | Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib f NCT02121990 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Completed | Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mu NCT01989546 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer NCT01899599 | Glycotope GmbH | Phase 2 |
| Completed | VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian NCT01666444 | Celgene | Phase 2 |
| Terminated | Vitamin D for Women at Increased Risk of Developing Ovarian, Fallopian, or Primary Peritoneal Cancer NCT01744821 | Northwestern University | N/A |
| Completed | A Study LY2228820 for Recurrent Ovarian Cancer NCT01663857 | Eli Lilly and Company | Phase 1 / Phase 2 |
| Completed | CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer NCT01652079 | Massachusetts General Hospital | Phase 2 |
| Withdrawn | DCVax-L Vaccination With CD3/CD28 Costimulated Autologous T-Cells for Recurrent Ovarian or Primary Peritoneal NCT00603460 | University of Pennsylvania | Phase 1 / Phase 2 |
| Completed | Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 and BRCA 2) Mutations and Solid NCT01339650 | AbbVie (prior sponsor, Abbott) | Phase 1 |
| Completed | Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer NCT01220154 | David O'Malley | Phase 1 |
| Terminated | AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2) NCT01281254 | Amgen | Phase 3 |
| Terminated | A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Pri NCT01312389 | Abramson Cancer Center at Penn Medicine | Phase 1 / Phase 2 |
| Terminated | Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer NCT01312376 | Abramson Cancer Center at Penn Medicine | Phase 1 |
| Completed | Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer NCT01196741 | University College, London | Phase 2 / Phase 3 |
| Completed | Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers NCT01237067 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Panitumumab and Gemcitabine in Relapsed Ovarian Cancer NCT01296035 | Women and Infants Hospital of Rhode Island | Phase 2 |
| Completed | Phase II ABT-888 With Cyclophosphamide NCT01306032 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Vinorelbine and Gemcitabine Combination In Platinum Resistant Recurrent Ovarian Cancer NCT01196559 | The Catholic University of Korea | Phase 2 |
| Completed | TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for NCT01204749 | Amgen | Phase 3 |
| Completed | Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With Ovarian Cancer NCT01253681 | Amgen | Phase 1 |
| Completed | Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian NCT01219777 | Ritu Salani | Phase 1 |
| Completed | Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer NCT01105650 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Completed | Neoadjuvant Therapy for Ovarian Cancer NCT01146795 | Jason D. Wright | Phase 2 |
| Unknown | A Phase IIclinical Trial of Carboplatin and Paclitaxel or Carboplatin and Gemcitabine in Platinum-sensitive, R NCT01570582 | Korean Gynecologic Oncology Group | Phase 2 |
| Completed | Positron Emission Tomography/Computed Tomography (PET/CT) in Relapsed Ovarian Cancer (MK-0000-143) NCT00959582 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer NCT00928642 | Henry M. Jackson Foundation for the Advancement of Military Medicine | Phase 2 |
| Completed | Study of Paclitaxel in Patients With Ovarian Cancer NCT00989131 | Oasmia Pharmaceutical AB | Phase 3 |
| Active Not Recruiting | Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colo NCT00799110 | Beth Israel Deaconess Medical Center | Phase 2 |
| Completed | Single Arm Study of BSI-201 in Patients With BRCA-1 or BRCA-2 Associated Advanced Epithelial Ovarian, Fallopia NCT00677079 | Sanofi | Phase 2 |
| Completed | Hu3S193 in Treating Women With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer NCT00617773 | Recepta Biopharma | Phase 2 |
| Completed | Phase 1 Study of NY-ESO-1 Overlapping Peptides in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Ca NCT00616941 | Ludwig Institute for Cancer Research | Phase 1 |
| Completed | A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients NCT00526617 | AbbVie | Phase 1 |
| Completed | Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Th NCT00520013 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Phase 2 AMG 386 in Comb. Paclitaxel for Subjects With Advanced Recurrent Epithelial Ovarian or Primary Periton NCT00479817 | Amgen | Phase 2 |
| Completed | Safety Study of a Genetically Modified Adenovirus in Ovarian Cancer Patients NCT00562003 | University of Alabama at Birmingham | Phase 1 |
| Completed | A Study of Chemotherapy Treatment for Patients With Ovarian Cancer NCT00428610 | Eli Lilly and Company | Phase 2 |
| Completed | Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer NCT00436215 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma NCT00418093 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian Cancer NCT00466986 | Southeastern Gynecologic Oncology | Phase 2 |
| Completed | Cisplatin Induction With Paclitaxel Consolidation for Stage III-IV Epithelial Ovarian and Primary Peritoneal C NCT00314678 | John P. Fruehauf | Phase 2 |
| Completed | Trial of Pemetrexed and Carboplatin in Patients With Recurrent Ovarian or Primary Peritoneal Cancer NCT00489359 | Eli Lilly and Company | Phase 1 / Phase 2 |
| Completed | Study of Pemetrexed in the Treatment of Patients With Ovarian Cancer Who Have Failed Prior Platinum-Based Chem NCT00109096 | Eli Lilly and Company | Phase 2 |
| Completed | PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, NCT00059618 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma NCT00226915 | Japanese Gynecologic Oncology Group | Phase 3 |
| Completed | Phase II Study of Modified Triple Doublet Therapy in Women With Newly Diagnosed Mullerian Carcinoma NCT00157560 | Massachusetts General Hospital | Phase 2 |